NYSE:SQZ SQZ Biotechnologies - SQZ Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding SQZ Biotechnologies Please log in to your account or sign up in order to add this asset to your watchlist. $0.82 -0.01 (-1.20%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.79▼$0.8650-Day Range$0.67▼$2.6552-Week Range$0.65▼$8.21Volume112,771 shsAverage Volume162,318 shsMarket Capitalization$24.15 millionP/E RatioN/ADividend YieldN/APrice Target$7.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media SQZ Biotechnologies MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside845.1% Upside$7.75 Price TargetShort InterestHealthy1.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.50) to ($1.93) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector773rd out of 1,055 stocksBiological Products, Except Diagnostic Industry123rd out of 170 stocks 3.1 Analyst's Opinion Consensus RatingSQZ Biotechnologies has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.75, SQZ Biotechnologies has a forecasted upside of 845.1% from its current price of $0.82.Amount of Analyst CoverageSQZ Biotechnologies has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.37% of the float of SQZ Biotechnologies has been sold short.Short Interest Ratio / Days to CoverSQZ Biotechnologies has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SQZ Biotechnologies has recently increased by 2.45%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSQZ Biotechnologies does not currently pay a dividend.Dividend GrowthSQZ Biotechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SQZ. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows6 people have added SQZ Biotechnologies to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SQZ Biotechnologies insiders have not sold or bought any company stock.Percentage Held by Insiders18.70% of the stock of SQZ Biotechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions49.84% of the stock of SQZ Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SQZ Biotechnologies are expected to grow in the coming year, from ($3.50) to ($1.93) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SQZ Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SQZ Biotechnologies is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSQZ Biotechnologies has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About SQZ Biotechnologies (NYSE:SQZ) StockSQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.Read More Receive SQZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address SQZ Stock News HeadlinesJanuary 19, 2023 | msn.comSQZ Biotechnologies gets non-compliance notice from NYSEJanuary 18, 2023 | finance.yahoo.comSQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock ExchangeJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 16, 2022 | benzinga.comSQZ Biotechnologies's Return On Capital Employed OverviewDecember 6, 2022 | finance.yahoo.comSQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology CongressDecember 1, 2022 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZDecember 1, 2022 | markets.businessinsider.comAnalyst Ratings for SQZ BiotechnologiesDecember 1, 2022 | markets.businessinsider.comExpert Ratings for SQZ BiotechnologiesJanuary 31, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.December 1, 2022 | seekingalpha.comSQZ Biotech CEO steps down amid 60% workforce reduction, pause on some clinical programsDecember 1, 2022 | finance.yahoo.comRoche-partnered cell therapy company lays off most of its staff, loses CEO, CFONovember 30, 2022 | finance.yahoo.comSQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive OfficerNovember 12, 2022 | finance.yahoo.comSQZ Biotechnologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 10, 2022 | finance.yahoo.comSQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual MeetingNovember 9, 2022 | finance.yahoo.comSQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio UpdatesNovember 8, 2022 | finance.yahoo.comMultiple insiders bought SQZ Biotechnologies Company (NYSE:SQZ) stock earlier this year, a positive sign for shareholdersOctober 3, 2022 | benzinga.comSQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived ImmunotherapyOctober 3, 2022 | finance.yahoo.comSQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived ImmunotherapySeptember 26, 2022 | nasdaq.comIs SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Invest In Growth?September 12, 2022 | finance.yahoo.comSQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell TherapiesSeptember 6, 2022 | finance.yahoo.comSQZ Biotechnologies Announces Leadership TransitionAugust 11, 2022 | finance.yahoo.comWill SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?August 4, 2022 | seekingalpha.comSQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97MAugust 4, 2022 | finance.yahoo.comSQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio UpdatesJuly 30, 2022 | nasdaq.comSQZ Biotechnologies (NYSE:SQZ) shareholders have endured a 78% loss from investing in the stock a year agoJuly 12, 2022 | finance.yahoo.comSQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell ActivationJuly 11, 2022 | finance.yahoo.comSQZ Biotechnologies Appoints Micah Zajic as Chief Financial OfficerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SQZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address SQZ Company Calendar Last Earnings11/09/2022Today1/31/2023Next Earnings (Estimated)3/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNYSE:SQZ CUSIPN/A CIK1604477 Webwww.sqzbiotech.com Phone617-758-8672FaxN/AEmployees113Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.75 High Stock Price Forecast$15.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+845.1%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,740,000.00 Net Margins-355.20% Pretax Margin-355.20% Return on Equity-80.63% Return on Assets-40.80% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual Sales$27.10 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value$4.42 per share Price / Book0.19Miscellaneous Outstanding Shares29,450,000Free Float23,944,000Market Cap$24.15 million OptionableNot Optionable Beta2.79 Key ExecutivesDr. Howard Bernstein M.D. (Age 65)Ph.D., Interim CEO & Director Comp: $546.52kMr. Lawrence J. Knopf (Age 60)Gen. Counsel Comp: $478.04kDr. Robert S. Langer Jr. (Age 73)Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board Mr. Micah Zajic (Age 41)Chief Financial Officer Mr. Richard V. Capasso CPA (Age 60)Chief Accounting Officer Mr. David First (Age 58)Chief People Officer Dr. Marshelle Smith Warren M.D.Chief Medical OfficerIpsita Roymoulik Ph.D.Sr. VP of CMC & QUALITYMore ExecutivesKey CompetitorsCortexymeNASDAQ:CRTXElevation OncologyNASDAQ:ELEVAcorda TherapeuticsNASDAQ:ACORRubius TherapeuticsNASDAQ:RUBYMicrobot MedicalNASDAQ:MBOTView All CompetitorsInsiders & InstitutionsBalyasny Asset Management LLCBought 12,404 shares on 11/16/2022Ownership: 0.042%BlackRock Inc.Sold 8,433 shares on 11/15/2022Ownership: 0.945%Citadel Advisors LLCSold 46,350 shares on 11/15/2022Ownership: 0.057%683 Capital Management LLCBought 87,262 shares on 11/14/2022Ownership: 7.623%Ergoteles LLCSold 5,364 shares on 11/14/2022Ownership: 0.336%View All Insider TransactionsView All Institutional Transactions SQZ Stock - Frequently Asked Questions Should I buy or sell SQZ Biotechnologies stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SQZ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SQZ, but not buy additional shares or sell existing shares. View SQZ analyst ratings or view top-rated stocks. What is SQZ Biotechnologies' stock price forecast for 2023? 4 Wall Street analysts have issued 1-year target prices for SQZ Biotechnologies' stock. Their SQZ share price forecasts range from $2.00 to $15.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 850.9% from the stock's current price. View analysts price targets for SQZ or view top-rated stocks among Wall Street analysts. How have SQZ shares performed in 2023? SQZ Biotechnologies' stock was trading at $0.74 on January 1st, 2023. Since then, SQZ shares have increased by 10.1% and is now trading at $0.8150. View the best growth stocks for 2023 here. When is SQZ Biotechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023. View our SQZ earnings forecast. How were SQZ Biotechnologies' earnings last quarter? SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.12. The business had revenue of $3.45 million for the quarter, compared to the consensus estimate of $4.29 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 80.63% and a negative net margin of 355.20%. When did SQZ Biotechnologies IPO? (SQZ) raised $75 million in an IPO on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager. What is SQZ Biotechnologies' stock symbol? SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ." Who are SQZ Biotechnologies' major shareholders? SQZ Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amy W Schulman, Klavs F Jensen and Richard Capasso. View institutional ownership trends. How do I buy shares of SQZ Biotechnologies? Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is SQZ Biotechnologies' stock price today? One share of SQZ stock can currently be purchased for approximately $0.82. How much money does SQZ Biotechnologies make? SQZ Biotechnologies (NYSE:SQZ) has a market capitalization of $24.00 million and generates $27.10 million in revenue each year. The company earns $-68,740,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. How many employees does SQZ Biotechnologies have? The company employs 113 workers across the globe. How can I contact SQZ Biotechnologies? SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The official website for the company is www.sqzbiotech.com. The company can be reached via phone at 617-758-8672 or via email at investors@sqzbiotech.com. This page (NYSE:SQZ) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.